365 related articles for article (PubMed ID: 21649579)
21. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
23. Correlation between telomerase and mTOR pathway in cancer stem cells.
Dogan F; Biray Avci C
Gene; 2018 Jan; 641():235-239. PubMed ID: 29074462
[TBL] [Abstract][Full Text] [Related]
24. Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
Ding L; Ding L; Wang S; Wang S; Wang W; Wang W; Lv P; Lv P; Zhao D; Zhao D; Chen F; Chen F; Meng T; Meng T; Dong L; Dong L; Qi L; Qi L
Pharmacology; 2017; 99(3-4):188-195. PubMed ID: 27889779
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Kahraman DC; Kahraman T; Cetin-Atalay R
Mol Cancer Ther; 2019 Nov; 18(11):2146-2157. PubMed ID: 31439713
[TBL] [Abstract][Full Text] [Related]
26. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
27. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
[TBL] [Abstract][Full Text] [Related]
28. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
29. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
[TBL] [Abstract][Full Text] [Related]
30. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
31. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis.
Martelli AM; Chiarini F; Evangelisti C; Grimaldi C; Ognibene A; Manzoli L; Billi AM; McCubrey JA
Histol Histopathol; 2010 May; 25(5):669-80. PubMed ID: 20238304
[TBL] [Abstract][Full Text] [Related]
32. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
[TBL] [Abstract][Full Text] [Related]
33. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
34. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of rapamycin against glioblastoma cancer stem cells.
Mendiburu-Eliçabe M; Gil-Ranedo J; Izquierdo M
Clin Transl Oncol; 2014 May; 16(5):495-502. PubMed ID: 24043497
[TBL] [Abstract][Full Text] [Related]
36. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
37. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Zheng J; Zou X; Yao J
Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
[TBL] [Abstract][Full Text] [Related]
38. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
39. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]